



**PENSION HOSPITALIZATION AND BENEFIT PLAN  
JOINT INDUSTRY BOARD OF THE ELECTRICAL INDUSTRY**  
158-11 HARRY VAN ARSDALE JR. AVENUE • FLUSHING, N.Y. 11365  
TEL: (718) 591-2000 • FAX: (718) 380-7741 • www.jibe.org

September 2019

HARRY VAN ARSDALE JR.  
Founder

DR. GERALD FINKEL  
Chairman, Joint Industry Board  
of the Electrical Industry

**Trustees**  
STEVEN LAZZARO  
Chairman  
SANDRA MILAD-GIBSON  
Treasurer  
CHRISTOPHER ERIKSON  
Secretary  
THOMAS CLEARY  
Trustee  
VITO V. MUNDO  
Counsel

**Employer Representatives**  
ROBERT AMABILE  
ANDREW DRAZIC  
STEPHEN GIANOTTI  
KORY KLEINBERG  
STEVEN LAZZARO  
JOHN G. MARCATO  
SANDRA MILAD-GIBSON  
JERRY SCHAUDER  
RICHARD SOBEL

**Employee Representatives**  
THOMAS CAPURSO  
THOMAS CLEARY  
CHRISTOPHER ERIKSON  
CHRISTOPHER ERIKSON JR.  
WILLIAM HOFVING  
JOSEPH PROSCIA  
JOSEPH SANTI GATE  
LANCE VAN ARSDALE

**Important Information for all Active Participants and their Eligible Dependents**

**Gene Therapy Exclusion**

Dear Participant:

This is an important notice concerning the health benefits provided by the Pension, Hospitalization and Benefit Plan - Welfare Plan ("the Plan"). Please read this notice carefully and keep it with your copy of the Plan's Summary Plan Description ("SPD").

**The Plan does not cover gene therapy.**

**What is Gene therapy?**

Gene therapy is a technique that modifies a person's genes to treat or cure disease. Gene therapy can involve the following:

1. Replacing a gene that causes a medical problem with a gene which does not.
2. Adding a gene to help the body fight or treat a disease.
3. Inactivating a gene which causes a disease.

The Plan does not cover any charges related to gene therapy, whether those therapies have received FDA approval or are considered experimental or investigational. Illustrative examples of gene therapy include: Chimeric Antigen receptor T-cell (CAR-T), such as Kymriah and Yescarta. New applications for gene therapy are submitted every year.

**The following paragraph is for clarification purposes and will be added to the SPD section entitled "Exclusions and Limitations:"**

**"Charges in connection with any gene therapy treatments whether those therapies have received approval from the U.S. Food and Drug Administration ("FDA") or not or are considered experimental or investigational, including but not limited to CAR-T Therapies, such as Kymriah and Yescarta, Ocular Gene Therapies, such as Luxturna, and Spinal Muscular Atrophy treatments, such as Zolgensma."**

From time to time, the FDA approves new drugs, biologicals, and other treatment modalities. The Trustees reserve the right to decide if a new drug, biological, or other treatment modality will be covered on a case-by-case basis. The Trustees may base their decision on, among other things, industry practices and the recommendation of the manager of the Plan's Prescription Drug Program. From time to time, the Trustees will review these decisions and may decide to reverse the exclusion of any drug, biological, or treatment modality from coverage.

**You or your health care provider may call the MagnaCare dedicated line at 1-877-624-6210 with any questions or concerns.**

Sincerely,

Trustees of the Pension, Hospitalization and  
Benefit Plan of the Electrical Industry



## PENSION HOSPITALIZATION AND BENEFIT PLAN JOINT INDUSTRY BOARD OF THE ELECTRICAL INDUSTRY

158-11 HARRY VAN ARSDALE JR. AVENUE • FLUSHING, N.Y. 11365  
TEL: (718) 591-2000 • FAX: (718) 380-7741 • www.jibe.org

HARRY VAN ARSDALE JR.  
Founder

September 2019

### Important Information for all Retired Participants and their Eligible Dependents

#### Gene Therapy Exclusion

Dear Participant:

This is an important notice concerning the health benefits provided by the Pension, Hospitalization and Benefit Plan - Welfare Plan ("the Plan"). Please read this notice carefully and keep it with your copy of the Plan's Summary Plan Description ("SPD").

#### **The Plan does not cover gene therapy.**

#### **What is Gene therapy?**

Gene therapy is a technique that modifies a person's genes to treat or cure disease. Gene therapy can involve the following:

1. Replacing a gene that causes a medical problem with a gene which does not.
2. Adding a gene to help the body fight or treat a disease.
3. Inactivating a gene which causes a disease.

The Plan does not cover any charges related to gene therapy, whether those therapies have received FDA approval or are considered experimental or investigational. Illustrative examples of gene therapy include: Chimeric Antigen receptor T-cell (CAR-T), such as Kymriah, Yescarta. New applications for gene therapy are submitted every year.

#### **The following paragraph is for clarification purposes and will be added to the SPD section entitled "Exclusions and Limitations:"**

"Charges in connection with any gene therapy treatments whether those therapies have received approval from the U.S. Food and Drug Administration ("FDA") or not or are considered experimental or investigational, including, but not limited to CAR-T Therapies, such as Kymriah and Yescarta, Ocular Gene Therapies, such as Luxturna and Spinal Muscular Atrophy treatments, such as Zolgensma."

From time to time, the FDA approves new drugs, biologicals, and other treatment modalities. The Trustees reserve the right to decide if a new drug, biological, or other treatment modality will be covered on a case-by-case basis. The Trustees may base their decision on, among other things, industry practices and the recommendation of the manager of the Plan's Prescription Drug Program. From time to time, the Trustees will review these decisions and may decide to reverse the exclusion of any drug, biological, or treatment modality from coverage.

**You or your health care provider may call the MagnaCare dedicated line at 1-877-624-6210 with any questions or concerns.**

Sincerely,

Trustees of the Pension, Hospitalization and  
Benefit Plan of the Electrical Industry

DR. GERALD FINKEL  
Chairman, Joint Industry Board  
of the Electrical Industry

**Trustees**  
STEVEN LAZZARO  
Chairman  
SANDRA MILAD-GIBSON  
Treasurer  
CHRISTOPHER ERIKSON  
Secretary  
THOMAS CLEARY  
Trustee  
VITO V. MUNDO  
Counsel

**Employer Representatives**  
ROBERT AMABILE  
ANDREW DRAZIC  
STEPHEN GIANOTTI  
KORY KLEINBERG  
STEVEN LAZZARO  
JOHN G. MARCATO  
SANDRA MILAD-GIBSON  
JERRY SCHAUDER  
RICHARD SOBEL

**Employee Representatives**  
THOMAS CAPURSO  
THOMAS CLEARY  
CHRISTOPHER ERIKSON  
CHRISTOPHER ERIKSON JR.  
WILLIAM HOFVING  
JOSEPH PROSCIA  
JOSEPH SANTIGATE  
LANCE VAN ARSDALE

**“Grandfathered” Plan Status:**

The Pension, Hospitalization and Benefit Plan of the Electrical Industry - Retiree Plan (“the Plan”) believes this plan is a “grandfathered health plan” under the Patient Protection and Affordable Care Act (the Affordable Care Act). As permitted by the Affordable Care Act, a grandfathered health plan can preserve certain basic health coverage that was already in effect when that law was enacted. Being a grandfathered health plan means that your plan may not include certain consumer protections of the Affordable Care Act that apply to other plans, for example, the requirement for the provision of preventive health services without any cost sharing. However, grandfathered health plans must comply with certain other consumer protections in the Affordable Care Act, for example, the elimination of lifetime limits on benefits.

Questions regarding which protections apply and which protections do not apply to a grandfathered health plan and what might cause a plan to change from grandfathered health plan status can be directed to the Plan Administrator at the Joint Industry Board of the Electrical Industry at 718-591-2000. You may also contact the Employee Benefits Security Administration, U.S. Department of Labor at 1-866-444-3272 or [www.dol.gov/ebsa/healthreform](http://www.dol.gov/ebsa/healthreform). This website has a table summarizing which protections do and do not apply to grandfathered health plans.